A Phase 3 interventional study of OPN-375 in Bilateral Nasal Polyposis, sponsored by Optinose US Inc.. Completed at 31 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 72 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjects will be enrolled to obtain 10 completers.
The primary objective of this study is to evaluate the efficacy of intranasal administration of OPN-375 186 μg Twice a Day (BID) versus placebo in adolescents with bilateral nasal polyposis and nasal congestion by analyzing the reduction of nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning diary symptom scores and the reduction in total polyp grade at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale.
Optinose US Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects, if sexually active, must,
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks
Drug: OPN-375
Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
Drug: OPN-375
OPN-375, BID
Change in nasal congestion/obstruction symptoms (mild, moderate, severe) at the end of Week 4
Change in nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning (AM) diary symptom scores (ADS7-IA). The nasal symptom scale is what is used to score the nasal congestion/obstruction score, which is recorded in the diary. Nasal symptom scale is graded on a scale of 0=no symptom, 1=mild symptom, 2=moderate symptom, 3=severe symptom.
Time frame: 4 Weeks
Mean change from baseline at Week 16 in total polyp grade
Change in total polyp grade (sum of scores from both nasal cavities) at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril
Time frame: 16 Weeks
Change in bilateral polyp grade over time
nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril
Time frame: 16 Weeks
Percentage of subjects with a ≥1 point improvement in polyp grade
nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril
Time frame: 16 Weeks
Percentage of subject with a grade of 0 on at least one side of the nose
nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril
Time frame: 16 Weeks
Change in diary symptom scores for the symptoms of nasal congestion/obstruction, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)
Time frame: 16 Weeks
Change in diary symptom scores for the symptoms of rhinorrhea, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)
Time frame: 16 Weeks
Change in diary symptom scores for the symptoms of facial pain or pressure, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)
Time frame: 16 Weeks
Change in diary symptom scores for the sense of smell, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
Sense of smell will be scored on a scale from 0 (normal) to 3 (absent, no sense of smell)
Time frame: 16 Weeks
The proportions of subjects who have reductions in the AM and PM, instantaneous and reflective, average nasal congestion/obstruction symptom scores by 0.5 or more points from baseline to the end of the double-blind treatment phase
The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)
Time frame: 16 Weeks
Subjects will assess their global impression of change since starting the study drug using the PGIC scale
Subject global impression of change will be assessed using a subject-completed PGIC scale, with a single question rated from 1=very much improved to 7=very much worse
Time frame: 16 Weeks
Subjects will assess their change in quality of life since starting the study drug using the quality of life questionnaire (SN-5).
Quality of life assessment using the SN-5 Questionnaire, a subject/parent-completed questionnaire that consists of 5 specific symptoms-related questions (answered on a 7-point Likert scale on the frequency of symptoms, 1=none of the time, 7=all of the time), and 1 general overall quality of life question (answered on a visual analog scale from 0 to 10, worst to best).
Time frame: 16 Weeks
Proportion of subjects eligible for surgical intervention (independent of actual surgery performed)
The assessment criteria are as follows: * Subject has had moderate symptoms of congestion from nasal polyposis for at least 3 months. * Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for at least 6 weeks. * Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for at least 6 weeks. * Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score \> 2 in at least 1 nostril). Also assess each subject's eligibility for surgery based on specific of criteria (see Section 12) independent of whether the subject actually undergoes surgery.
Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety from physical examination-measuring weight
Assessment of safety from physical examination-weight measured in kg or lb
Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety from physical examination-measuring height
Assessment of safety from physical examination-height measured in cm or in
Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by recording the severity of AEs
Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe
Time frame: 16 Weeks
Assessment of safety by nasal examination
Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma
Time frame: 16 Weeks
Assessment of safety by ocular examination-visual acuity
Assessment of safety by performing visual acuity test assessment using eye chart. Separate recording for each eye in the form of a fraction, 20/...
Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Intraocular Pressure
Assessment of safety by averaging intraocular pressure measurement of 2 or 3 measurements to determine if it is \>21mmHg
Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Cataract Evaluation
Cataracts should be again assessed present or absent, If cataract is diagnosed, cataract type per localization should be specified and cataract should be graded 1=mild, 2=moderate, 3=pronounced, 4=severe
Time frame: Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety measuring vital signs (blood pressure)
Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)
Time frame: 16 Weeks
Assessment of safety measuring vital signs (pulse)
measure pulse in beats per minute (bpm)
Time frame: 16 Weeks
Assessment for safety from the collection of information for concomitant medications usage
Time frame: 16 Weeks
Assessment of pharmacokinetics - AUC(0-t) (pg*hr/mL)
PK Laboratory to determine the concentrations of fluticasone propionate \[AUC(0-t) (pg\*hr/mL) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
Time frame: 8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUC(0-∞) (pg*hr/mL)
PK Laboratory to determine the concentrations of fluticasone propionate \[AUC(0-∞) (pg\*hr/mL) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
Time frame: 8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUCex (%)
PK Laboratory to determine the concentrations of fluticasone propionate \[AUCex (%) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
Time frame: 8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - Cmax (pg/mL)
PK Laboratory to determine the concentrations of fluticasone propionate \[Cmax (pg/mL) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
Time frame: 8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - tmax (h)
PK Laboratory to determine the concentrations of fluticasone propionate \[tmax (h) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
Time frame: 8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - t1/2 (h)
PK Laboratory to determine the concentrations of fluticasone propionate \[t1/2 (h) measurement\] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.
Time frame: 8 hours, 1 to 2 weeks before randomization
Ran from Dec 2018 to primary completion in Mar 2026, 87 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Optinose US Inc.